3 Top Canadian Healthcare Stocks for Growth Investors

Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and two other healthcare stocks may have flown under the radar of recession-proofing investors.

| More on:
Pills pharma

Image source: Getty Images

With an ageing population, a continent facing the possibility of recession, an industry making cutting-edge breakthroughs, one might think that an investment in health care is a no-brainer. Let’s take a look at three innovative stocks on the TSX that will give investors with a broad financial horizon a mix of defensive characteristics, capital gains, and dividends.


A biopharmaceutical company with a focus on clinical-stage cancer therapy and other immunotherapies, IMV (TSX:IMV)(NASDAQ:IMV) is committed to developing drugs that allow extended exposure of antigens to the human immune system. It’s one of the top pharma stocks on the TSX, and it’s trading near a 52-week low. While value investors may wish to wait for the knife to finish falling, there’s an opportunity to catch a tailwind should positive drug trial data materialize.

This stock has had a rough time of it lately but remains a solid play if you like beaten-up healthcare tickers. Snatching up shares in a stock that company insiders have been buying is almost always a smart play, as it indicates that there’s confidence in a price climb. With IMV’s position in the market lending a degree of defensiveness to your investment, you could be looking at a wide profit margin in a solidly recession-proof sector.

While it doesn’t pay a dividend, IMV stock has gained 200% in the last two years and could continue to grow as new immunotherapies are made more effective, more applicable, and more easily available to patients. Given that IMV’s patented system fills a key niche in modern medicine, there’s a lot of possibility for growth here.


When it comes to overlooked healthcare stocks, personal mobility is an excellent investment idea if you’re looking for a recession-ready sector to harden up your dividend portfolio. Savaria (TSX:SIS) is the wide-moat option in this space and pays a decent dividend yield of 3.38% at today’s knocked-down price of $12.43. Revenue grew by 55% with adjusted EBITDA clearing 30% in a first quarter that should have growth investors salivating.

The stair-lift maker is active in a range of markets, manufacturing home elevators, wheelchair lifts, and other innovative adaptations for people with mobility challenges. The solutions available come under the trident of Accessibility, Adapted Vehicles, and Span. The latter segment covers therapeutics such as pressure management devices and support surfaces, while the adapted vehicles section covers van conversions.


Touted as a growth stock in the healthcare space, Vancouver-headquartered biotech company Zymeworks (TSX:ZYME)(NYSE:ZYME) rocketed on favourable clinical data this year. Growing 71.75% in the past year, Zymeworks is focused on innovative cancer treatments such as alternatives to hormone therapy and chemotherapy. When it held its IPO in May 2017, it was the largest domestic debut from a biotech company in over 10 years.

In other words, Zymeworks is a big deal and a solid buy for a healthcare investor looking for stocks with a lot of growth potential. An award-winning company in a niche sector, long-term investors seeking a canny capital gains play should consider stacking shares this cancer-focused biotech wunderkind.

The bottom line

With two cancer-treatment companies and a wide-moat mobility solutions business on the table, growth investors looking to make some smart money in a recession-hardy sector have some inviting options in this trio of stocks. Given their different approaches, both Zymeworks and IMV could be held without worrying too much about overexposure, while Savaria would make for a complementary passive-income investment.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. Savaria is a recommendation of Hidden Gems Canada.

More on Dividend Stocks

Silver coins fall into a piggy bank.
Dividend Stocks

A TFSA Contribution Room of $88,000 and 1 Dividend Aristocrat Can Make You $172,330 Richer

A high-yield Dividend Aristocrat in the energy sector is a suitable holding for Canadians with $88,000 available contribution rooms in…

Read more »

Dollar symbol and Canadian flag on keyboard
Dividend Stocks

2 Dividend Stocks to Buy Now Under $50

Here are two of the best under-$50 dividend stocks you can buy in Canada right now.

Read more »

Dividend Stocks

If I Could Only Buy 1 Stock Before 2023, This Would be it!

If you could buy 1 stock before 2023, what would it be? Here’s the stock I’m considering, and I think…

Read more »

Beautiful holiday decorated background with christmas gift boxes ,fir. christmas holiday concept
Dividend Stocks

3 Dividend Stocks to Help Offset Holiday Spending

The holidays are here, and so is the seasonal spending. Offset some of those costs by putting your investment cash…

Read more »

edit Businessman using calculator next to laptop
Dividend Stocks

The 3 Passive-Income Stocks I’m Buying Next and Never Selling

These passive-income stocks have a proven track record of growth and a solid sector that will guarantee income for decades.

Read more »

oil and gas pipeline
Dividend Stocks

Enbridge Stock Rose More Than 4.5% in November: Is it a Buy Today?

Enbridge is having a good year. Are more gains on the way for the stock?

Read more »

worry concern
Dividend Stocks

3 Budget Mistakes Almost Everyone Makes

Leave these budget mistakes in 2022 and enter 2023 with more cash on hand and a better way of spending.

Read more »

Target. Stand out from the crowd
Dividend Stocks

Got $1,000? Buy These Up-and-Coming Stocks Before They Take Off

These growth stocks beat the long-term market returns and could continue delivering above-average growth in the coming years.

Read more »